

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: **Yu, et al.**

Application Number: 09/589,288

Group Art Unit: 1647

Filed: June 8, 2000

Examiner: B. Bunner

Title: **Methods of Treatment Using Antibodies** Atty. Docket No. PF343P3C5
to Neutrokin-alpha (as amended)

**SECOND SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT
PURSUANT TO 37 C.F.R. §§ 1.56 and 1.97(c)**

RECEIVED

DEC 08 2003

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

TECH CENTER 1600/2900

In accordance with the duty of disclosure imposed by 37 C.F.R. § 1.56 to inform the Patent and Trademark Office of all references coming to the attention of each individual associated with the filing or prosecution of the subject application, which are or may be material to the patentability of an claim of the subject application, Attorneys/Agents for Applicants hereby direct the Examiner's attention to references C1-C10 listed on the attached revised form PTO/SB/08. Copies of references C1-C10 are submitted herewith.

Identification of the listed references is not to be construed as an admission of any individual associated with the filing or prosecution of the subject application that such reference is available as "prior art" against the subject application. Furthermore, Applicants do not waive any rights to appropriate action to establish patentability over the listed document should it be applied as a reference against the claims of the subject application.

Applicants respectfully request that the Examiner review the listed references and that the references be made of record in the file history of the application.

Pursuant to 37 C.F.R. § 1.97(c), since this Information Disclosure Statement is being filed before the mailing date of a final action under §1.113, a notice of allowance under §1.311, or an action that otherwise closes prosecution in the application, a fee of \$180.00 is

believed due in connection herewith. If Applicants are in error, please charge any additional required fees to Human Genome Sciences, Inc., Deposit Account No. 08-3425.

Respectfully submitted,

Date: December 2, 2003



Kenley K. Hoover (Reg. No. 40,302)
Agent for Applicants

Human Genome Sciences, Inc.
9410 Key West Avenue
Rockville, MD 20850
Telephone: (301) 610-5771

KKH/MS/vsr

Substitute for form 1449A/B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Application Number	09/589,288-Conf. #1519
				Filing Date	June 8, 2000
				First Named Inventor	Guo-Liang Yu
				Art Unit	1647
				Examiner Name	B. Bunner
Sheet	1	of	1	Attorney Docket Number	PF343P3C5

RECEIVED

DEC 08 2003

TECH CENTER 1600/2900

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	C1	Waldmann, TA, "Immunotherapy: Past, Present and Future," Nature Medicine 9:269-277, (2003).	
	C2	Janeway, C. & P. Travers. (1994) Immunobiology: The Immune System in Health and Disease, (Current Biology Ltd./Garland Publishing, London), pp 1:15, 1:16 and 11:19.	
	C3	Weinblatt, ME et al., Methotrexate in rheumatoid arthritis. A five-year prospective multicenter study. Arthritis and Rheumatism. (1994) 37:1492-1498.	
	C4	Wise, CM et al., Methotrexate in nonrenal lupus and undifferentiated connective tissue disease - a review of 36 patients. The Journal of Rheumatology. (1996) 23:1005-1010.	
	C5	Brazelton, TR and RE Morris. Molecular mechanism of action of new xenobiotic immunosuppressive drugs: tacrolimus (FK506), sirolimus (rapamycin), mycophenolate mofetil and leflunomide. Current Opinion in Immunology. (1996) 8:710-720.	
	C6	Goldblum, R, Therapy of rheumatoid arthritis with mycophenolate mofetil. Clinical and Experimental Rheumatology. (1993) 11 suppl 8:S117-119.	
	C7	Ciruelo, E et al., Cumulative rate of relapse of lupus nephritis after successful treatment with cyclophosphamide. Arthritis and Rheumatism. (1996) 39:2028-2034.	
	C8	Huard, et al., T cell costimulation by the TNF ligand BAFF. The Journal of Immunology. (2001) 167(11):6225-31.	
	C9	Kayagaki, N et al., BAFF/BLyS receptor 3 binds the B cell survival factor BAFF ligand through a discrete surface loop and promotes processing of NF-kappaB2. Immunity (2002) 10:515-24.	
	C10	Abbas et al., Cellular and Molecular Immunology (W.B. Saunders Company: Philadelphia) 1991, pp. 362 and 365.	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--